Bambusa’s $90M series A; Recursion-backed accelerator’s ‘pre-seed’ fund: Venture Report

A bispecifics developer drew the past week’s largest venture round, while a Recursion-backed accelerator in Salt Lake City will have a new fund dedicated to supporting start-ups that will miss out on SBIR grants due to cuts at NIH.

On Feb. 13, Bambusa Therapeutics Inc. followed last year’s seed round with a $90 million series A, with which it will develop a pipeline of bispecifics for immune and inflammatory indications. Ra Capital Management led the round, with Janus Henderson Investors, Redmile Group, Invus and ADAR1 Capital Management joining the syndicate...